Option chain shows key data for Cidara Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Cidara Therapeutics.

Cidara Therapeutics (NASDAQ:CDTX) Stock, Option Chain

Cidara Therapeutics

Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.

defence analysts

News

Initiation

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

CDTX

CYTK

FLUT

IMNM

This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Caterpillar - logo

ACON

AIRE

ATNI

BMRN

BNAI

BPTS

BRFH

BRKL

CSSE

CYCC

ESGL

FCFS

HRYU

HUIZ

ILAG

JAKK

OPTN

ORGO

PCSA

POAI

PTSI

SGBX

SNBR

SPCB

STRA

ULBI

ZAPP

Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Stock Market

Movers

ASTI

HKIT

IBRX

ISUN

NUWE

SERV

SNAP

VIST

Why Teradyne Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket

Cidara Therapeutics Inc

RBC Capital analyst Gregory Renza initiates coverage on Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Outperform rating and announces Price Target of $34.

Price Target

RBC Capital Initiates Coverage On Cidara Therapeutics with Outperform Rating, Announces Price Target of $34

WBB Securities analyst Stephen Brozak maintains Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Strong Buy and raises the price target from $40 to $45.

WBB Securities Maintains Strong Buy on Cidara Therapeutics, Raises Price Target to $45

Biotech

General

Cidara Therapeutics Completes Enrollment Of Its Phase 2b NAVIGATE Trial Evaluating CD388 In The Prevention Of Seasonal Influenza

<h3>Gainers</h3>
<ul>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) shares moved upwards by 71.4% to $1.68 during Thursday's pre-market session. The market value of their outstanding shares is at $2.7 million. </li>
<li>Conduit Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) stock rose 55.36% to $0.14. The market value of their outstanding shares is at $14.7 million. </li>
<li>Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) shares rose 28.96% to $19.5. The market value of their outstanding shares is at $137.4 million. </li>
<li>Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) stock rose 27.46% to $75.55. The company's market cap stands at $548.9 million. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) stock increased by 16.88% to $4.5. The market value of their outstanding shares is at $65.3 million. </li>
<li>DarioHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRIO#NASDAQ">DRIO</a>) stock increased by 14.1% to $0.89. The market value of their outstanding shares is at $30.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Pyxis Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYXS#NASDAQ">PYXS</a>) stock fell 43.5% to $2.16 during Thursday's pre-market session. The company's market cap stands at $128.3 million. </li>
<li>Perspective Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CATX#AMEX">CATX</a>) shares declined by 27.23% to $4.49. The market value of their outstanding shares is at $303.4 million. </li>
<li>Kura Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KURA#NASDAQ">KURA</a>) stock decreased by 25.52% to $11.85. The company's market cap stands at $921.5 million. </li>
<li>BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) stock decreased by 22.42% to $0.42. The company's market cap stands at $33.8 million. </li>
<li>Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) stock declined by 20.0% to $0.27. The market value of their outstanding shares is at $3.8 million. </li>
<li>Assembly Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASMB#NASDAQ">ASMB</a>) stock fell 11.06% to $13.36. The market value of their outstanding shares is at $84.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ASMB

BDRX

BLRX

CATX

DRIO

KURA

PYXS

SLXN

SMLR

WORX

12 Health Care Stocks Moving In Thursday's Pre-Market Session

WIIM

Cidara Therapeutics shares are trading higher. The company announced a $105 million private placement.

Cidara Therapeutics shares are trading lower after the company announced a $105 million private placement.

Cidara Therapeutics Secures $105M In Private Placement; Closing Expected November 25, 2024

HC Wainwright &amp; Co. analyst Ed Arce reiterates Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Buy and maintains $24 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Cidara Therapeutics, Maintains $24 Price Target

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Guggenheim analyst Seamus Fernandez initiated coverage on Cidara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Buy rating and announced a price target of $33. Cidara Therapeutics shares closed at $13.11 on Thursday. <a href="https://www.benzinga.com/quote/cdtx/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>RBC Capital analyst Leonid Timashev initiated coverage on Cytokinetics, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with an Outperform rating and announced a price target of $80. Cytokinetics shares closed at $55.84 on Thursday. <a href="https://www.benzinga.com/quote/cytk/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stephens &amp; Co. analyst Sudan Loganathan initiated coverage on Immunome, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNM#NASDAQ">IMNM</a>) with an Overweight rating and announced a price target of $30. Immunome shares closed at $12.54 on Thursday. <a href="https://www.benzinga.com/quote/imnm/analyst-ratings">See </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">how other analysts view this stock</a>.</li>
<li>Jefferies analyst Dennis Ding initiated coverage on Inhibikase Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKT#NASDAQ">IKT</a>) with a Buy rating and announced a price target of $8. Inhibikase Therapeutics shares closed at $2.78 on Thursday. <a href="https://www.benzinga.com/quote/ikt/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Ben Shelley initiated coverage on Flutter Entertainment plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLUT#NYSE">FLUT</a>) with a Buy rating and announced a price target of $306. Flutter Entertainment shares closed at $237.98 on Thursday. <a href="https://www.benzinga.com/quote/flut/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying CYTK stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="544" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08084118/image-92-1024x544.png" alt="" class="wp-image-637640" style="width:627px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08084118/image-92-1024x544.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08084118/image-92-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08084118/image-92-768x408.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08084118/image-92.png 1237w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/41820056/how-to-earn-500-a-month-from-nvidia-stock-after-trump-win">How To Earn $500 A Month From Nvidia Stock After Trump Win</a></li>
</ul>

Guggenheim analyst Seamus Fernandez initiates coverage on Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Buy rating and announces Price Target of $33.

Guggenheim Initiates Coverage On Cidara Therapeutics with Buy Rating, Announces Price Target of $33

Cidara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>), a biotechnology company using its proprietary Cloudbreak&#xAE;&nbsp;platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced two presentations at OPTIONS XII for the Control of Influenza conference, to be held September 29 through October 2, 2024 in Brisbane, Australia. The presentations, one oral and one poster, will highlight safety and pharmacokinetic (PK) data from clinical studies of CD388, Cidara's influenza drug-Fc conjugate (DFC) candidate.

Cidara Therapeutics Announces Two Presentations On Innovative Drug-Fc Conjugate, CD388, At The 2024 OPTIONS XII For The Control Of Influenza Conference

Cidara Therapeutics Doses First Subjects In Phase 2b NAVIGATE Trial Of CD388 In The Prevention Of Seasonal Influenza

Trading Halt: Halt status updated at 4:30:00 PM ET: Quotation Resumption: News and Resumption Times

Guidance

Management

Cidara Therapeutics Estimates Will Incur Charges Of About $1.2M For Severance Payments And Employee Benefits, Primarily In Q4 2024; Expects To Initiate Phase 2b Clinical Trial Of CD388 For Prevention Of Influenza In Q3 2024

Cidara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>), a biotechnology company using its proprietary Cloudbreak&#xAE; platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced a reduction in its workforce to focus on the clinical development of CD388, the Company's novel DFC candidate for influenza A and B. The planned reduction impacts approximately 30% of the Cidara workforce. &nbsp;
These strategic initiatives are expected to substantially reduce capital needs and allow Cidara to focus on its planned Phase 2b and potential subsequent trials investigating CD388 as a single-dose, universal preventative for influenza A and B. The Company continues business development discussions for its oncology DFC programs, including CBO421, a CD73 inhibitor, which recently received IND-clearance to commence a Phase 1 study.

Cidara Therapeutics Restructures Workforce By 30% To Focus On Planned Clinical Development Of CD388

Trading Halt: Halted at 4:00:15 p.m. ET - Trading Halt: Halt News Pending

HC Wainwright &amp; Co. analyst Ed Arce upgrades Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) from Neutral to Buy and announces $24 price target.

Upgrades

HC Wainwright & Co. Upgrades Cidara Therapeutics to Buy, Announces $24 Price Target

Cantor Fitzgerald analyst Louise Chen reiterates Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Overweight.

Cantor Fitzgerald Reiterates Overweight on Cidara Therapeutics

Warning: CDTX is at high risk of performing badly

Cidara Therapeutics GAAP EPS of -$2.38 beats by $1.87

"The recent initiation of our Phase 2b NAVIGATE clinical trial, which will evaluate the efficacy and safety of CD388 for the pre-exposure prophylax...

Cidara Therapeutics reports Q3 EPS ($2.45), consensus ($4.25)

Needham analyst Joseph Stringer maintained a Buy rating on Cidara Therapeutics (CDTX – Research Report) today and set a price target of $25.00. Jos...

Positive Outlook for Cidara Therapeutics Amid Strategic Advancements and Financial Stability

Cidara Therapeutics sold its Rezayo business to concentrate entirely on its unique MDC-producing Cloudbreak platform which has already produced several promising drug candidates like CD388, a very promising clinical-stage anti-influenza MDC.

Cidara Therapeutics' Unique Cloudbreak Platform And Its Promise In Influenza And Oncology

Cidara Therapeutics (CDTX) has entered into a securities purchase agreement with certain investors to raise up to approximately $105M in gross proc...

Cidara Therapeutics to issue 3.89M shares at $14.912 in private placement

Cidara Therapeutics shares surge on $105M equity private placement

Cidara: Potential To Change Flu Prophylaxis Landscape With CD388

RBC Capital analyst Gregory Renza initiated coverage of Cidara Therapeutics (CDTX) with an Outperform rating and $34 price target The firm sees the...

Cidara Therapeutics initiated with an Outperform at RBC Capital

CMXHF

RHHBY

Health Care

Press Releases

Cidara Therapeutics Strengthens its Scientific Advisory Board with Infectious Disease Experts

Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenza

Cidara Therapeutics Announces Two Presentations on Innovative Drug-Fc Conjugate, CD388, at the 2024 OPTIONS XII for the Control of Influenza Conference

Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Cidara Therapeutics Announces Two Presentations on Drug-Fc Conjugate, CD388, at IDWeek 2024

Cidara Therapeutics to Participate in Two Upcoming November Investor Conferences

Earnings

Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Cidara Therapeutics to Participate in Evercore 7th Annual HealthCONx Conference

Financing

Cidara Therapeutics Announces $105 Million Private Placement

Cidara Therapeutics Completes Enrollment of Phase 2b NAVIGATE Trial Evaluating CD388 for Prevention of Seasonal Influenza

Comments

Cidara Therapeutics

Cidara Therapeutics (CDTX) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga